Cedars-sinai Medical Center

Dianhua Jiang

Carol Jiurong Liang

Paul W Noble

Ting Xie

The invention relates to methods for treating or preventing progressive pulmonary fibrosis in a subject.

Methods for targeting the immune checkpoint PD1 pathway for treating pulmonary fibrosis

The described invention provides a method for reducing progression of lung fibrosis after a lung injury comprising administering a therapeutic amount of a therapeutic agent, wherein the therapeutic amount is effective: (a) to modulate expression of a T-box transcription factor in a population of cells in lung; and (b) to reduce proliferation of the population of cells in lung expressing the T-box transcription factor. According to some embodiments the T-box transcription factor is Tbx4.

Method effective to modulate expression of T-box protein 4 (Tbx4) for reducing progression of lung fibrosis after a lung injury

The described invention provides a method of treating a lung injury at risk of progressing to a fibrotic lung disease in a subject in need thereof comprising administering to the subject a composition comprising a therapeutic amount of IL-6 polypeptide, hyaluronan (HA), mimetics thereof, pharmaceutically acceptable salts thereof, or combinations thereof, wherein the therapeutic amount is effective to increase renewal of alveolar epithelial cell 2 (AEC2) stem cells, to repair the injury, to reduce lung fibrosis, or a combination thereof.

Methods for reducing severity of pulmonary fibrosis

The described invention provides a method for identifying a therapeutic compound effective to reduce invasiveness of fibroblasts characterized by a highly invasive phenotype obtained from a subject with idiopathic pulmonary fibrosis.

Growing community of inventors

Encino, CA, United States of America

Dianhua Jiang